BioPharm

The World's Sixth-largest Independent Biotech Company Chooses ValGenesis's VLMS Offering to Manage its Validation Process

Retrieved on: 
Monday, October 1, 2018
Clinical data management, Business, Economy, Clinical research, Pharmaceutical industry, Quality, Validation, Validity, BioPharm

SAN FRANCISCO, Oct. 1, 2018 /PRNewswire/ --ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the world's sixth-largest independent biotech company has chosen ValGenesis's 100% paperless Validation Lifecycle Management System to manage its corporate validation lifecycle process.

Key Points: 
  • SAN FRANCISCO, Oct. 1, 2018 /PRNewswire/ --ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the world's sixth-largest independent biotech company has chosen ValGenesis's 100% paperless Validation Lifecycle Management System to manage its corporate validation lifecycle process.
  • With a 125-year legacy in clinical trials and life-saving treatments, this highly focused research-driven biopharmaceutical company believes in doing more than just treating diseases.
  • Recognizing that traditional, manual, paper-based validation processes are costly and inefficient, the company selected ValGenesis Enterprise VLMSan electronic, paperless, cloud-based SaaS solution that well meets its lifecycle validation needs.
  • ValGenesis, Inc. provides the first enterprise application that manages the corporate validation lifecycle process.

TOT BIOPHARM's 16,000L-capacity monoclonal antibodies production base put into operation

Retrieved on: 
Thursday, June 21, 2018
Biotechnology, Biology, Pharmaceutical industry, Nature, BioPharm, Clinical data management, Computational biology, Biopharmaceutical

The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.

Key Points: 
  • The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.
  • With the new facility, TOT BIOPHARM will also be able to produce both biologic drugs and small molecular drugs at commercial scale.
  • TOT BIOPHARM Company Limited, established in Suzhou Industrial Park in 2010, is a high-tech enterprise specialized in the R&D, production and marketing of innovative oncology drugs.
  • In a move to enhance the company's production capacity and further meet the demand for oncology drugs worldwide, TOT BIOPHARM broke ground on the construction of the second phase for a mAb production base in 2016.

TOT BIOPHARM's 16,000L-capacity monoclonal antibodies production base put into operation

Retrieved on: 
Wednesday, June 20, 2018
Biotechnology, Biology, Pharmaceutical industry, Nature, BioPharm, Clinical data management, Computational biology, Biopharmaceutical

The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.

Key Points: 
  • The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.
  • With the new facility, TOT BIOPHARM will also be able to produce both biologic drugs and small molecular drugs at commercial scale.
  • TOT BIOPHARM Company Limited, established in Suzhou Industrial Park in 2010, is a high-tech enterprise specialized in the R&D, production and marketing of innovative oncology drugs.
  • In a move to enhance the company's production capacity and further meet the demand for oncology drugs worldwide, TOT BIOPHARM broke ground on the construction of the second phase for a mAb production base in 2016.

TOT BIOPHARM's 16,000L-capacitymonoclonal antibodies production base put into operation

Retrieved on: 
Wednesday, June 20, 2018
Biotechnology, Biology, Pharmaceutical industry, Nature, BioPharm, Clinical data management, Computational biology, Biopharmaceutical

The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.

Key Points: 
  • The 13,000-square meter facility will be capable of meeting all-around demand from the biopharmaceutical sector for upstream research and development, pilot-scale production, clinical trial drugs production and commercial production.
  • With the new facility, TOT BIOPHARM will also be able to produce both biologic drugs and small molecular drugs at commercial scale.
  • TOT BIOPHARM Company Limited, established in Suzhou Industrial Park in 2010, is a high-tech enterprise specialized in the R&D, production and marketing of innovative oncology drugs.
  • In a move to enhance the company's production capacity and further meet the demand for oncology drugs worldwide, TOT BIOPHARM broke ground on the construction of the second phase for a mAb production base in 2016.